Partner Stuart Fross was quoted in a Board IQ article, “With Zero-Fee Funds, What’s a Board to Do at 15(c) Time?,” covering what Fidelity’s almost 20 no-fee funds mean for boards during their 15(c) contract renewal process.
Fross shares insights on all effects of the changes, including that, because of these changes, the need to have data on market behavior, investments and funds is now not vital during the 15(c) process. He also said that it’s now unnecessary to do the Gartenberg factors because there is no profitability in it. In addition, though, he points out other outcomes that will come of Fidelity’s new structure, saying that the no-fee funds make it a possibility to negotiate a fund’s investment management fee.
Fross shares insights on all effects of the changes, including that, because of these changes, the need to have data on market behavior, investments and funds is now not vital during the 15(c) process. He also said that it’s now unnecessary to do the Gartenberg factors because there is no profitability in it. In addition, though, he points out other outcomes that will come of Fidelity’s new structure, saying that the no-fee funds make it a possibility to negotiate a fund’s investment management fee.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”